Hearings on the first Actos lawsuit against the drug’s manufacturer are expected to begin after a status conference in March. The lawsuit alleges that Takeda Pharmaceuticals failed to warn patients about the increased risks of bladder cancer when taking the diabetes drug for more than one year.
The hearings will be the first step in moving these Actos lawsuits forward since many of the cases were consolidated. The company may face more than 10,000 lawsuits that were filed after a study found that Actos could increase the risk of cancer.
The Food and Drug Administration approved a new warning for Actos in August 2011 after multiple studies confirmed this cancer risk when using the drug over an extended period. A five-year study revealed that patients who use Actos for more than one year are up to 40% more likely to develop bladder cancer.